Prothena公共 PRTA 深 沪
等待开盘 10-01 09:30:00 美东时间
9.76
0.000
0.00%
华盛通- 最 高9.85
- 今 开9.73
- 成交量 98.91万股
- 最 低 9.50
- 昨 收 9.76
- 总市值 5.25亿
- 52周最高 18.88
- 市盈率 静 --
- 换手率 1.84%
- 52周最低 4.32
- 委 比 25.00%
- 总股本 5382.70万
- 历史最高 79.749
- 量 比 1.04
- 振 幅 3.59%
- 历史最低 4.32
- 每 手 1
- 风险率 4.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多FDA Tightens Safety Guidelines For Biogen Leqembi Alzheimer's Therapy
The FDA now requires earlier MRI screening for Alzheimer's drug Leqembi to detect ARIA-E, a rare but serious side effect, aiming to improve treatment safety for patients.
08-29 22:09
Piper Sandler Maintains Overweight on Prothena Corp, Lowers Price Target to $15
Piper Sandler analyst Yasmeen Rahimi maintains Prothena Corp (NASDAQ:PRTA) with a Overweight and lowers the price target from $81 to $15.
08-28 22:27
Prothena Reports Phase 1 Results For PRX012 In Alzheimer's; Explores Partnerships To Advance PRX012 And TfR-Linked Preclinical Program
As previously communicated, Prothena plans to explore potential partnership interest to advance PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibodyPhase 1 ASCENT clinical program established
08-28 04:15
Chardan Capital Maintains Buy on Prothena Corp, Maintains $18 Price Target
Chardan Capital analyst Rudy Li maintains Prothena Corp (NASDAQ:PRTA) with a Buy and maintains $18 price target.
08-05 18:21
Earnings Scheduled For August 4, 2025
Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is likely to rep...
08-04 16:32
A Glimpse of Prothena Corp's Earnings Potential
Prothena Corp (NASDAQ:PRTA) will release its quarterly earnings report on Monda...
08-02 05:05
Prothena Secures Leadership with New Executive Agreements
The latest update is out from Prothena ( ($PRTA) ). On July 30, 2025, Prothena ...
07-31 05:52
Roche's Itovebi combination for breast cancer gets EU nod
Roche (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF) said that the European Commission has approved its oral cancer drug, Itovebi (inavolisib), to be used alongside palbociclib and fulvestrant for breast c...
07-23 21:59
Roche COPD biologic astegolimab fails in phase 3 for COPD
Astegolimab, an anti-ST2 monoclonal antibody designed to block signaling of IL-33 under development by Roche's (OTCQX:RHHBY) Genentech unit, failed to meet its primary endpoint in a phase 3 trial for ...
07-22 02:52
FDA rejects Genentec's cancer drug label expansion
Genentech, part of the Roche Group (OTCQX:RHHBY) (OTCQX:RHHBF) (OTCPK:RHHVF), announced that the U.S. FDA has rejected its request to expand the use of its cancer drug Columvi. The company had applied...
07-19 02:45
